Russell Investments Group’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-56,192
| Closed | -$1.13M | – | 4461 |
|
|
2026
Q1 | $1.13M | Sell |
56,192
-57
| -0.1% | -$919 | ﹤0.01% | 2155 |
|
|
2025
Q4 | $908K | Buy |
56,249
+53
| +0.1% | +$702 | ﹤0.01% | 2261 |
|
|
2025
Q3 | $684K | Buy |
56,196
+3,127
| +6% | +$43.2K | ﹤0.01% | 2346 |
|
|
2025
Q2 | $600K | Buy |
53,069
+41
| +0.1% | +$501 | ﹤0.01% | 2270 |
|
|
2025
Q1 | $612K | Sell |
53,028
-80,544
| -60% | -$822K | ﹤0.01% | 2227 |
|
|
2024
Q4 | $1.13M | Buy |
133,572
+17,580
| +15% | +$182K | ﹤0.01% | 1956 |
|
|
2024
Q3 | $1.34M | Buy |
115,992
+37,310
| +47% | +$469K | ﹤0.01% | 1893 |
|
|
2024
Q2 | $927K | Buy |
+78,682
| New | +$918K | ﹤0.01% | 2001 |
|
|
2023
Q3 | – | Sell |
-1,004
| Closed | -$9.04K | – | 3574 |
|
|
2023
Q2 | $9.04K | Hold |
1,004
| – | – | ﹤0.01% | 2983 |
|
|
2023
Q1 | $7.89K | Hold |
1,004
| – | – | ﹤0.01% | 2914 |
|
|
2022
Q4 | $6.79K | Hold |
1,004
| – | – | ﹤0.01% | 2855 |
|
|
2022
Q3 | $14K | Buy |
+1,004
| New | +$14K | ﹤0.01% | 2841 |
|
|
2022
Q1 | – | Sell |
-18,705
| Closed | -$247K | – | 2849 |
|
|
2021
Q4 | $247K | Hold |
18,705
| – | – | ﹤0.01% | 2666 |
|
|
2021
Q3 | $326K | Hold |
18,705
| – | – | ﹤0.01% | 2622 |
|
|
2021
Q2 | $448K | Hold |
18,705
| – | – | ﹤0.01% | 2635 |
|
|
2021
Q1 | $480K | Sell |
18,705
-3,781
| -17% | -$99.3K | ﹤0.01% | 2540 |
|
|
2020
Q4 | $425K | Sell |
22,486
-98,467
| -81% | -$1.69M | ﹤0.01% | 2494 |
|
|
2020
Q3 | $1.52M | Buy |
+120,953
| New | +$1.51M | ﹤0.01% | 1857 |
|
Other funds holding KALV
Russell Investments Group's KALV Position: Q2 2026 in Review
Russell Investments Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 56,192 shares — an estimated $1.13M sold.
Russell Investments Group first reported a position in KALV in Q3 2020 and held it in 18 quarters. The position peaked at $1.52M in Q3 2020. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Russell Investments Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Russell Investments Group sold 56,192 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.13M.
- Russell Investments Group first reported a position in KalVista Pharmaceuticals in Q3 2020 and held it in 18 quarters.
- Russell Investments Group's KalVista Pharmaceuticals position peaked at $1.52M in Q3 2020.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.